Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimer's Dementia
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
This study aimed to determine the serum levels of free L-carnitine, acetyl-L-carnitine and 34 acyl-L-carnitine in healthy subjects and in patients with or at risk of Alzheimer's disease. Twenty-nine patients with probable Alzheimer's disease, 18 with mild cognitive impairment of the amnestic type, 24 with subjective memory complaint and 46 healthy subjects were enrolled in the study, and the levels of carnitine and acyl-carnitines were measured by tandem mass spectrometry. The concentrations of acetyl-L-carnitine progressively decreased passing from healthy subjects group (mean±SD, 5.6±1.3 μmol/L) to subjective memory complaint (4.3±0.9 μmol/L), mild cognitive impairment (4.0±0.53 μmol/L), up to Alzheimer's disease (3.5±0.6 μmol/L) group (p<0.001). The differences were significant for the comparisons: healthy subjects vs. subjective memory complaint, mild cognitive impairment or Alzheimer's disease group; and subjective memory complaint vs. Alzheimer's disease group. Other acyl-carnitines, such as malonyl-, 3-hydroxyisovaleryl-, hexenoyl-, decanoyl-, dodecanoyl-, dodecenoyl-, myristoyl-, tetradecenoyl-, hexadecenoyl-, stearoyl-, oleyl- and linoleyl-L-carnitine, showed a similar decreasing trend, passing from healthy subjects to patients at risk of or with Alzheimer's disease. These results suggest that serum acetyl-L-carnitine and other acyl-L-carnitine levels decrease along the continuum from healthy subjects to subjective memory complaint and mild cognitive impairment subjects, up to patients with Alzheimer's disease, and that the metabolism of some acyl-carnitines is finely connected among them. These findings also suggest that the serum levels of acetyl-L-carnitine and other acyl-L-carnitines could help to identify the patients before the phenotype conversion to Alzheimer's disease and the patients who would benefit from the treatment with acetyl-L-carnitine. However, further validation on a larger number of samples in a longitudinal study is needed before application to clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Vellas, B., Guigoz, Y., Garry, P. J., Nourhashemi, F., Bennahum, D., Lauque, S., & Albarede, J.-L. (1999) · Nutrition · doi:10.1016/s0899-9007(98)00171-3 · Cited by 2,161
The Mitochondrial Carnitine Palmitoyltransferase System — From Concept to Molecular Analysis
McGarry, J. D., & Brown, N. F. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.00001.x · Cited by 1,616 · cited 1×
“CPT-I (located in the inner side of the outer mitochondrial membrane) and CPT-II (in the inner leaflet of the inner mitochondrial matrix) are crucial for the β-oxidation of fatty acids in the mitochondria, by facilitating their transport across the mitochondrial membranes [36, 37].”
BackgroundThe Diagnosis and Management of Mild Cognitive Impairment: A Clinical Review
Langa, K. M., & Levine, D. A. (2014) · JAMA · doi:10.1001/jama.2014.13806 · Cited by 1,337 · cited 1×
“This condition is at high risk for developing AD and is suitable for possible therapeutic intervention [1, 2].”
BackgroundMemory loss in Alzheimer's disease
Jahn, H. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.4/hjahn · Cited by 653 · cited 1×
“In effect, increasing evidences suggest that AD is a heterogeneous disorder that includes several subtypes with different pathogenic mechanisms and progression [48, 49].”
BackgroundGlucose metabolism, gray matter structure, and memory decline in subjective memory impairment
Scheef, L., Spottke, A., Daerr, M., Joe, A., Striepens, N., Kölsch, H., Popp, J., Daamen, M., Gorris, D., Heneka, M. T., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826c1a8d · Cited by 277
Montgomery, S. A., Thal, L. J., & Amrein, R. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200303000-00001 · Cited by 209
González‐Domínguez, R., García, A., García‐Barrera, T., Barbas, C., & Gómez‐Ariza, J. L. (2014) · ELECTROPHORESIS · doi:10.1002/elps.201400196 · Cited by 119
Acetyl-l-carnitine for dementia
Hudson, S. A., & Tabet, N. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003158 · Cited by 86 · cited 3×
“The authors of a recent meta-analysis [14] concluded that there is no sufficient evidence to recommend the routine use of ALC in clinical practice and that more studies, particularly on pharmacokinetics of ALC, are needed [14].”
BackgroundResultInfluential
Cited by
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials
Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., Smesny, S., Sen, Z. D., Guo, A. C., Oler, E., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000408 · Cited by 507
Yin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Horgusluoglu, E., Neff, R., Song, W., Wang, M., Wang, Q., Arnold, M., Krumsiek, J., Galindo‐Prieto, B., Ming, C., Nho, K., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12468 · Cited by 175
Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update
Pennisi, M., Lanza, G., Cantone, M., D’Amico, E., Fisicaro, F., Puglisi, V., Vinciguerra, L., Bella, R., Vicari, E., & Malaguarnera, G. (2020) · Nutrients · doi:10.3390/nu12051389 · Cited by 87
“Interestingly, the findings of a recent study suggested a decrease of serum ALC and other acylcarnitine concentrations along the continuum from healthy subjects to AD patients through subjective memory complaints and MCI, with acyl-carnitines metabolism being finely connected among them [81].”
BackgroundYulug, B., Altay, O., Li, X., Hanoglu, L., Cankaya, S., Lam, S., Velioglu, H. A., Yang, H., Coskun, E., Idil, E., et al. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00336-2 · Cited by 79
“showed a progressive decrease in carnitine serum levels in individuals shifting from normal status to AD, suggesting that decreased serum concentrations of carnitine may predispose them to AD [118].”
BackgroundTan, Y. J., Wong, B. Y. X., Vaidyanathan, R., Sreejith, S., Chia, S. Y., Kandiah, N., Ng, A. S. L., & Zeng, L. (2021) · Journal of Alzheimer's Disease Reports · doi:10.3233/adr-210311 · Cited by 48
Garbarino, V. R., Palavicini, J. P., Melendez, J., Barthelemy, N. R., He, Y., Kautz, T. F., Lopez-Cruzan, M., Mathews, J. J., Xu, P., Zhang, B., et al. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00591 · Cited by 26
“Alternatively, it is possible that the changes observed in this small open-label pilot are due to normal ADRD related disease progression, as reductions in LPE [86], PC [87,88], and type-speci fi c acylcar-nities [89,90], have been associated with AD progression.”
Borkowski, K., Liang, N., Zhao, N., Arnold, M., Huynh, K., Karu, N., Mahmoudiandehkordi, S., Kueider-Paisley, A., Kanekiyo, T., Bu, G., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00888-z · Cited by 7
Metadata
- Authors
- Cristofano, A., Sapere, N., La Marca, G., Angiolillo, A., Vitale, M., Corbi, G., Scapagnini, G., Intrieri, M., Russo, C., Corso, G., & Di Costanzo, A.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-05-19
- Volume
- 11
- Issue
- 5
- Pages
- e0155694
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2394583211
- Cited by
- 99
- References
- 9
- FWCI
- 3.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.